{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T18:57:28Z","timestamp":1793905048666,"version":"4.8.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Beijing Natural Science Foundation Project"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis and limited first-line treatments. This phase Ib\/II randomized trial (NCT05218889) investigated the efficacy and safety of surufatinib plus camrelizumab and nab-paclitaxel\/S-1 (NASCA) versus nab-paclitaxel and gemcitabine in patients with locally advanced or metastatic PDAC. The primary endpoints were dose-limiting toxicities and the recommended phase II dose (RP2D) of surufatinib in phase Ib, and the objective response rate (ORR) in phase II. Phase Ib used a 3\u2009+\u20093 dose-escalation design to determine the RP2D of surufatinib in six patients, which was established at 200\u2009mg. In phase II, patients were randomized 1:1 to receive the NASCA (45 patients) or nab-paclitaxel and gemcitabine (45 patients). NASCA group showed an ORR of 51.1% (23\/45) versus 24.4% (11\/45) in the nab-paclitaxel and gemcitabine group (odds ratio 3.2, 95% CI 1.3\u20138.2, <jats:italic>p<\/jats:italic>\u2009=\u20090.01). The median progression-free survival (PFS) was 7.9 vs. 5.3 months (HR 0.63, 95% CI 0.40\u20130.99, <jats:italic>p<\/jats:italic>\u2009=\u20090.045). The median overall survival was 13.0 vs. 11.0 months (HR 0.77, 95% CI 0.47\u20131.28, <jats:italic>p<\/jats:italic>\u2009=\u20090.318). The most common Grade \u22653 treatment-related adverse event was decreased neutrophil count (33.3% vs. 35.6%). In the NASCA group, enrichment of CD8<jats:sup>+<\/jats:sup> and CD8<jats:sup>+<\/jats:sup>PD-1<jats:sup>+<\/jats:sup> cells, a high baseline M1\/M2 macrophage ratio, and a reduction in CA19-9 levels at weeks 6 and 12 were associated with improved PFS compared to patients without these features. The NASCA regimen showed promising efficacy with tolerable safety relative to nab-paclitaxel and gemcitabine for locally advanced or metastatic PDAC.<\/jats:p>","DOI":"10.1038\/s41392-025-02441-2","type":"journal-article","created":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T23:02:16Z","timestamp":1760310136000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["First-line treatment with chemotherapy, surufatinib (an angio-immuno kinase inhibitor), and camrelizumab (an anti-PD-1 antibody) for locally advanced or metastatic pancreatic ductal adenocarcinoma: a phase Ib\/II randomized study"],"prefix":"10.1038","volume":"10","author":[{"given":"Ru","family":"Jia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Yan","family":"Si","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng-Jiao","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-Chao","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang-Fang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao-Miao","family":"Gou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao-Li","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Rong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao-Yue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Shan","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Qi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quan-Li","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Kuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang-Hai","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,13]]},"reference":[{"key":"2441_CR1","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel, R. L., Giaquinto, A. N. & Jemal, A. Cancer statistics, 2024. CA Cancer J. Clin. 74, 12\u201349 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"2441_CR2","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74, 229\u2013263 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"2441_CR3","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1016\/j.cell.2023.02.014","volume":"186","author":"CJ Halbrook","year":"2023","unstructured":"Halbrook, C. J., Lyssiotis, C. A., Pasca di Magliano, M. & Maitra, A. Pancreatic cancer: advances and challenges. Cell 186, 1729\u20131754 (2023).","journal-title":"Cell"},{"key":"2441_CR4","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff, D. D. et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N. Engl. J. Med. 369, 1691\u20131703 (2013).","journal-title":"N. Engl. J. Med."},{"key":"2441_CR5","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy, T. et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med. 364, 1817\u20131825 (2011).","journal-title":"N. Engl. J. Med."},{"key":"2441_CR6","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/S0140-6736(23)01366-1","volume":"402","author":"ZA Wainberg","year":"2023","unstructured":"Wainberg, Z. A. et al. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial. Lancet 402, 1272\u20131281 (2023).","journal-title":"Lancet"},{"key":"2441_CR7","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1158\/1078-0432.CCR-17-3099","volume":"24","author":"ZI Hu","year":"2018","unstructured":"Hu, Z. I. et al. Evaluating mismatch repair deficiency in pancreatic adenocarcinoma: challenges and recommendations. Clin. Cancer Res. 24, 1326\u20131336 (2018).","journal-title":"Clin. Cancer Res."},{"key":"2441_CR8","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1001\/jamaoncol.2019.1588","volume":"5","author":"EM O\u2019Reilly","year":"2019","unstructured":"O\u2019Reilly, E. M. et al. Durvalumab with or without tremelimumab for patients with metastatic pancreatic ductal adenocarcinoma: a phase 2 randomized clinical trial. JAMA Oncol. 5, 1431\u20131438 (2019).","journal-title":"JAMA Oncol."},{"key":"2441_CR9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s44276-023-00028-4","volume":"2","author":"C Morizane","year":"2024","unstructured":"Morizane, C. et al. A Phase 2 study of nivolumab in combination with modified FOLFIRINOX for metastatic pancreatic cancer. BJC Rep. 2, 3 (2024).","journal-title":"BJC Rep."},{"key":"2441_CR10","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1146\/annurev-pathmechdis-031621-024600","volume":"18","author":"MH Sherman","year":"2023","unstructured":"Sherman, M. H. & Beatty, G. L. Tumor microenvironment in pancreatic cancer pathogenesis and therapeutic resistance. Annu. Rev. Pathol. 18, 123\u2013148 (2023).","journal-title":"Annu. Rev. Pathol."},{"key":"2441_CR11","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13045-020-01030-w","volume":"14","author":"J Tao","year":"2021","unstructured":"Tao, J. et al. Targeting hypoxic tumor microenvironment in pancreatic cancer. J. Hematol. Oncol. 14, 14 (2021).","journal-title":"J. Hematol. Oncol."},{"key":"2441_CR12","doi-asserted-by":"publisher","first-page":"7181","DOI":"10.1158\/0008-5472.CAN-16-0300","volume":"76","author":"ME Gilles","year":"2016","unstructured":"Gilles, M. E. et al. Nucleolin targeting impairs the progression of pancreatic cancer and promotes the normalization of tumor vasculature. Cancer Res. 76, 7181\u20137193 (2016).","journal-title":"Cancer Res."},{"key":"2441_CR13","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","volume":"15","author":"D Fukumura","year":"2018","unstructured":"Fukumura, D. et al. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat. Rev. Clin. Oncol. 15, 325\u2013340 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2441_CR14","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1200\/EDBK_237987","volume":"39","author":"M Datta","year":"2019","unstructured":"Datta, M. et al. Reprogramming the tumor microenvironment to improve immunotherapy: emerging strategies and combination therapies. Am. Soc. Clin. Oncol. Educ. Book 39, 165\u2013174 (2019).","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"2441_CR15","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/s41392-024-01857-6","volume":"9","author":"H Sha","year":"2024","unstructured":"Sha, H. et al. First-line penpulimab (an anti-PD1 antibody) and anlotinib (an angiogenesis inhibitor) with nab-paclitaxel\/gemcitabine (PAAG) in metastatic pancreatic cancer: a prospective, multicentre, biomolecular exploratory, phase II trial. Signal Transduct. Target Ther. 9, 143 (2024).","journal-title":"Signal Transduct. Target Ther."},{"key":"2441_CR16","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1111\/j.1349-7006.2010.01793.x","volume":"102","author":"B Chuah","year":"2011","unstructured":"Chuah, B. et al. Comparison of the pharmacokinetics and pharmacodynamics of S-1 between Caucasian and East Asian patients. Cancer Sci. 102, 478\u2013483 (2011).","journal-title":"Cancer Sci."},{"key":"2441_CR17","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/S1470-2045(21)00692-6","volume":"23","author":"YK Kang","year":"2022","unstructured":"Kang, Y. K. et al. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 23, 234\u2013247 (2022).","journal-title":"Lancet Oncol."},{"key":"2441_CR18","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1016\/S1470-2045(12)70363-7","volume":"13","author":"YS Hong","year":"2012","unstructured":"Hong, Y. S. et al. S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial. Lancet Oncol. 13, 1125\u20131132 (2012).","journal-title":"Lancet Oncol."},{"key":"2441_CR19","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1093\/annonc\/mdx816","volume":"29","author":"Y Yamada","year":"2018","unstructured":"Yamada, Y. et al. S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial. Ann. Oncol. 29, 624\u2013631 (2018).","journal-title":"Ann. Oncol."},{"key":"2441_CR20","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1200\/JCO.24.00795","volume":"43","author":"C Li","year":"2025","unstructured":"Li, C. et al. Pathologic response of phase III study: perioperative camrelizumab plus rivoceranib and chemotherapy versus chemotherapy for locally advanced gastric cancer (DRAGON IV\/CAP 05). J. Clin. Oncol. 43, 464\u2013474 (2025).","journal-title":"J. Clin. Oncol."},{"key":"2441_CR21","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/S0140-6736(16)30583-9","volume":"388","author":"K Uesaka","year":"2016","unstructured":"Uesaka, K. et al. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet 388, 248\u2013257 (2016).","journal-title":"Lancet"},{"key":"2441_CR22","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1200\/JCO.2012.43.3680","volume":"31","author":"H Ueno","year":"2013","unstructured":"Ueno, H. et al. Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. J. Clin. Oncol. 31, 1640\u20131648 (2013).","journal-title":"J. Clin. Oncol."},{"key":"2441_CR23","doi-asserted-by":"publisher","first-page":"e2145515","DOI":"10.1001\/jamanetworkopen.2021.45515","volume":"5","author":"Y Takumoto","year":"2022","unstructured":"Takumoto, Y., Sasahara, Y., Narimatsu, H. & Akazawa, M. Comparative outcomes of first-line chemotherapy for metastatic pancreatic cancer among the regimens used in Japan: a systematic review and network meta-analysis. JAMA Netw. Open 5, e2145515 (2022).","journal-title":"JAMA Netw. Open"},{"key":"2441_CR24","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1002\/jso.24147","volume":"113","author":"M Suenaga","year":"2016","unstructured":"Suenaga, M. et al. S-1 plus nab-paclitaxel is a promising regimen for pancreatic cancer in a preclinical model. J. Surg. Oncol. 113, 413\u2013419 (2016).","journal-title":"J. Surg. Oncol."},{"key":"2441_CR25","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1007\/s00432-020-03442-0","volume":"147","author":"Y Zong","year":"2021","unstructured":"Zong, Y. et al. Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine as first-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma: a randomized study. J. Cancer Res. Clin. Oncol. 147, 1529\u20131536 (2021).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"2441_CR26","doi-asserted-by":"publisher","first-page":"12657","DOI":"10.2147\/CMAR.S263773","volume":"12","author":"Y Zong","year":"2020","unstructured":"Zong, Y. et al. Efficacy and safety of nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine for first-line chemotherapy in advanced pancreatic ductal adenocarcinoma. Cancer Manag. Res. 12, 12657\u201312666 (2020).","journal-title":"Cancer Manag. Res."},{"key":"2441_CR27","doi-asserted-by":"publisher","first-page":"e1406","DOI":"10.1093\/oncolo\/oyae171","volume":"29","author":"M Jin","year":"2024","unstructured":"Jin, M. et al. Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine in patients with advanced pancreatic cancer: a multicenter, randomized, phase II study. Oncologist 29, e1406\u2013e1418 (2024).","journal-title":"Oncologist"},{"key":"2441_CR28","doi-asserted-by":"publisher","first-page":"92401","DOI":"10.18632\/oncotarget.21359","volume":"8","author":"Y Shi","year":"2017","unstructured":"Shi, Y. et al. Nab-paclitaxel plus S-1 in advanced pancreatic adenocarcinoma (NPSPAC): a single arm, single center, phase II trial. Oncotarget 8, 92401\u201392410 (2017).","journal-title":"Oncotarget"},{"key":"2441_CR29","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.927654","volume":"26","author":"H Cui","year":"2020","unstructured":"Cui, H. et al. A Chinese retrospective multicenter study of first-line chemotherapy for advanced pancreatic cancer. Med. Sci. Monit. 26, e927654 (2020).","journal-title":"Med. Sci. Monit."},{"key":"2441_CR30","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1007\/s00423-021-02321-7","volume":"407","author":"Q Liu","year":"2022","unstructured":"Liu, Q. et al. Nab-paclitaxel plus S-1 with or without PD-1 inhibitor in pancreatic ductal adenocarcinoma with only hepatic metastases: a retrospective cohort study. Langenbecks Arch. Surg. 407, 633\u2013643 (2022).","journal-title":"Langenbecks Arch. Surg."},{"key":"2441_CR31","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s40265-021-01489-y","volume":"81","author":"YY Syed","year":"2021","unstructured":"Syed, Y. Y. Surufatinib: first approval. Drugs 81, 727\u2013732 (2021).","journal-title":"Drugs"},{"key":"2441_CR32","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/S1470-2045(20)30493-9","volume":"21","author":"J Xu","year":"2020","unstructured":"Xu, J. et al. Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 21, 1489\u20131499 (2020).","journal-title":"Lancet Oncol."},{"key":"2441_CR33","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1016\/S1470-2045(20)30496-4","volume":"21","author":"J Xu","year":"2020","unstructured":"Xu, J. et al. Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 21, 1500\u20131512 (2020).","journal-title":"Lancet Oncol."},{"key":"2441_CR34","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1007\/s00432-021-03898-8","volume":"149","author":"Y Cao","year":"2023","unstructured":"Cao, Y. et al. Surufatinib plus toripalimab in patients with advanced solid tumors: a single-arm, open-label, phase 1 trial. J. Cancer Res. Clin. Oncol. 149, 779\u2013789 (2023).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"2441_CR35","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s13045-023-01422-8","volume":"16","author":"S Chen","year":"2023","unstructured":"Chen, S. et al. Nab-paclitaxel and gemcitabine plus camrelizumab and radiotherapy versus nab-paclitaxel and gemcitabine alone for locally advanced pancreatic adenocarcinoma: a prospective cohort study. J. Hematol. Oncol. 16, 26 (2023).","journal-title":"J. Hematol. Oncol."},{"key":"2441_CR36","doi-asserted-by":"publisher","first-page":"161","DOI":"10.3892\/ol.2024.14293","volume":"27","author":"X Guo","year":"2024","unstructured":"Guo, X. et al. Efficacy of nab\u2011paclitaxel vs. gemcitabine in combination with S\u20111 for advanced pancreatic cancer: a multicenter phase II randomized trial. Oncol. Lett. 27, 161 (2024).","journal-title":"Oncol. Lett."},{"key":"2441_CR37","doi-asserted-by":"publisher","first-page":"7111","DOI":"10.7150\/jca.60379","volume":"12","author":"HW Li","year":"2021","unstructured":"Li, H. W. & Tang, S. L. Colony stimulating factor-1 and its receptor in gastrointestinal malignant tumors. J. Cancer 12, 7111\u20137119 (2021).","journal-title":"J. Cancer"},{"key":"2441_CR38","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.1158\/1538-7445.AM2023-2781","volume":"83","author":"S Gao","year":"2023","unstructured":"Gao, S. et al. Abstract 2781: mechanism study of surufatinib on the optimized strategy of AG plus PD-1 antibody treatment in pancreatic cancer. Cancer Res. 83, 2781\u20132781 (2023).","journal-title":"Cancer Res."},{"key":"2441_CR39","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1200\/JCO.2024.42.3_suppl.687","volume":"42","author":"SR Chandana","year":"2024","unstructured":"Chandana, S. R. et al. Kinetics of CA19-9 decline in a randomized phase III study of irinotecan liposome injection, oxaliplatin, 5-fluorouracial\/leucovorin (NALIRIFOX) or nab-paclitaxel plus gemcitabine (GEM+NABP) in patients who have not previously received chemotherapy for metastatic adenocarcinoma of the pancreas (NAPOLI 3). J. Clin. Oncol. 42, 687\u2013687 (2024).","journal-title":"J. Clin. Oncol."},{"key":"2441_CR40","doi-asserted-by":"publisher","first-page":"S1426","DOI":"10.1016\/j.annonc.2022.08.063","volume":"33","author":"L Wang","year":"2022","unstructured":"Wang, L. et al. LBA61 HR070803 plus 5-FU\/LV versus placebo plus 5-FU\/LV in second-line therapy for gemcitabine-refractory locally advanced or metastatic pancreatic cancer: a multicentered, randomized, double-blind, parallel-controlled phase III trial (HR-IRI-APC). Ann. Oncol. 33, S1426 (2022).","journal-title":"Ann. Oncol."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02441-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02441-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02441-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T17:03:26Z","timestamp":1760807006000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02441-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,13]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2441"],"URL":"https:\/\/doi.org\/10.1038\/s41392-025-02441-2","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,13]]},"assertion":[{"value":"26 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Yu-Qi Wang is employed by Nanjing Geneseeq Technology Inc. All other authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki and Good Clinical Practice recommendations. Ethics approval was granted by the Ethics Committee of Chinese PLA General Hospital (S2021-228-03).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All participants provided written informed consent prior to enrollment in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}],"article-number":"339"}}